Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

Peer-reviewed publications

Take a look at the Optune publications

Unprecedented 5-year survival data for newly diagnosed glioblastoma published in JAMA

Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.

Journal of the American Medical Association

Stupp R, Taillibert S, Kanner A, et al.
2017;318(23):2­3­0­6­-­2­3­1­6.

Copyright 2017 American Medical Association. All rights reserved.

Click here to view the abstract

2017 article from The ASCO Post on the unprecedented 5-year survival results seen with Optune + TMZ in EF-14

‘Out-of-the-box’ approach plus temozolomide extends survival in glioblastoma.

The ASCO Post

Goodman A.
http://www.ascopost.com/issues/may-10-2017/out-of-the-box-approach-plus-temozolomide-extends-survival-in-glioblastoma. Updated May 10, 2017. Accessed May 23, 2017.

Click here to view the article

Landmark 5-year survival analysis of the EF-14 trial in newly diagnosed glioblastoma

Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): final results of a randomized, multicenter, phase III trial.

2017 Annual Meeting of the American Association for Cancer Research (AACR)

Stupp R, Hegi ME, Idbaih A, et al.
2017; Abstract LBA AACR CT007.

Click here to view the abstract

The EF-14 trial: Pivotal phase 3 data for newly diagnosed glioblastoma published in JAMA

Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial.

Journal of the American Medical Association

Stupp R, Taillibert S, Kanner AA, et al.
2015;314(23):2­5­3­5­-­2­5­4­3.

Copyright 2015 American Medical Association. All rights reserved.

Click here to view the article

The EF-11 trial: Pivotal phase 3 data for recurrent glioblastoma published in the European Journal of Cancer

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality

European Journal of Cancer

Stupp R, Wong ET, Kanner AA, et al.
2012;48(14):2­1­9­2­-­2­2­0­2.

Copyright 2012 Elsevier. All rights reserved.

Click here to download now

Management of dermatologic adverse events

Characterization and management of dermatologic adverse events with the NovoTTF‑100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.

Seminars in Oncology

Lacouture ME, Davis ME, Elzinga G, et al.
2014;41(3 suppl 4);S­1­-­S­1­4.

Copyright 2014 Elsevier Inc. All rights reserved.

Click here to download now

Results from the NovoTAL™ System User Study

NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study

World Journal of Surgical Oncology

Chaudhry A, Benson L, Varshaver M, et al.
2015;13:316. doi: 10.1186/s1­2­9­5­7­-­0­1­5­-­0­7­2­2­-­3.

Click here to download now

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).